1 – 10 of 137
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Modeling anti-tumor immune responses using patient-derived melanoma organoids
- Contribution to journal › Article
- 2025
-
Mark
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma : a Danish population-based study
- Contribution to journal › Article
-
Mark
Lymphomas : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Contribution to journal › Article
-
Mark
EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma
- Contribution to journal › Article
-
Mark
The Anatomy of Interprofessional Collaboration Around Recommendations in the Intensive Care Unit: An Exploration After Serious Illness Care Training
- Contribution to journal › Article
-
Mark
Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH) : a randomised, open-label, phase 2/3 superiority trial
- Contribution to journal › Article
-
Mark
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review
- Contribution to journal › Scientific review
-
Mark
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy : Results from the prospective GHSG–NLG phase II BVB trial
- Contribution to journal › Letter
-
Mark
Serious illness conversations and quality of end-of-life care in patients with hematological malignancies-a retrospective quality improvement study
- Contribution to journal › Article
